US Market Report for Tissue Heart Valves 2018 - MedCore

  • ID: 4435266
  • Report
  • Region: United States
  • 395 pages
  • iData Research
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Boston Scientific
  • Cryolife
  • Karl Storz
  • Microline Surgical
  • SentreHeart
  • MORE
The vast majority of commercially available tissue valves are xenograft valves derived from animals. Usually, the valves are porcine, meaning from a pig, or bovine, meaning from a cow. The porcine heart is most similar to the human heart and therefore represents the best anatomical fit for replacement. The tissue of the pericardial sac is particularly well suited for a valve leaflet due to its extremely durable physical properties. Before implantation, the tissue undergoes multiple chemical treatments to make it suitable for replacement in the human heart.

The tissue is sterilized so that the biological markers are removed, thereby eliminating a response from the host's immune system. The primary advantage of tissue over mechanical valves is that tissue valves are much more biocompatible and thus a patient who receives a tissue valve does not require life-long anti-coagulation therapy. However, a disadvantage of tissue valves is that they are not as durable and typically last between 15 and 20 years before requiring replacement. Nevertheless, advances in polymer coatings have made tissue valves more durable than ever before.

Furthermore, several aortic tissue valve replacement devices under development that are currently undergoing clinical trials in the U.S. or awaiting FDA approval may be implanted percutaneously.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Boston Scientific
  • Cryolife
  • Karl Storz
  • Microline Surgical
  • SentreHeart
  • MORE
EXECUTIVE SUMMARY
U.S. CARDIAC SURGERY AND HEART VALVE DEVICE MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
PROCEDURE NUMBERS
PROCEDURE CODES INVESTIGATED
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY

1. RESEARCH METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecasts and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring

2. DISEASE OVERVIEW
2.1 BASIC ANATOMY
2.1.11 Coronary Artery Disease
2.1.12 Myocardial Infarction
2.1.13 Angina Pectoris
2.1.14 Heart Valve Disease
2.1.15 Congestive Heart Failure

3. PRODUCT PORTFOLIO
3.1.1 Tissue Heart Valves
3.1.2 Mechanical Tissue Heart Valves
3.1.3 Annuloplasty Repair Devices
3.1.4 Transcatheter Aortic Valve Replacement Devices
3.1.5 Transcatheter Mitral Valve Repair Devices
3.1.6 On-Pump Coronary Artery Bypass Devices
3.1.7 Off-Pump Coronary Artery Bypass Devices
3.1.8 Endoscopic Vessel Harvesting Devices
3.1.9 Anastomosis Assist Devices
3.1.10 Transmyocardial Revascularization Devices
3.1.11 Ventricular Assist Devices
3.1.12 Intra-Aortic Balloon Pump Device
3.1.13 Temporary Artificial Heart Replacement Device
3.1.14 Remote Hemodynamic Monitoring System Devices
3.1.15 Patent Foramen Ovale Devices
3.1.16 Atrial & Ventricular Septal Defect Device
3.1.17 Left Atrial Appendage Closure Device
3.1.18 Extracorporeal Membrane Oxygenation Machine
3.2 FDA RECALLS
3.2.1 MAQUET
3.2.2 Medtronic
3.2.3 HeartWare Inc
3.3 CLINICAL TRIALS
3.3.1 Medtronic
3.3.2 St. Jude Medical
3.3.3 Abiomed
3.3.4 Heartware Inc

4.
4. TISSUE HEART VALVE MARKET
4.1 INTRODUCTION
4.2 MARKET OVERVIEW
4.2.1 Tissue Heart Valve Market by Device Type
4.2.2 Tissue Heart Valve Market by Tissue Type
4.3 MARKET ANALYSIS AND FORECAST
4.3.1 Total Tissue Heart Valve Market
4.3.2 Total Tissue Heart Valve Market by Device Type
4.3.2.1 Stented Tissue Heart Valve Market
4.3.2.2 Stentless Tissue Heart Valve Market
4.3.2.3 Sutureless Tissue Heart Valve Market
4.3.3 Total Tissue Heart Valve Market by Tissue
4.3.3.1 Xenograft Tissue Heart Valve Market
4.3.3.2 Allograft Tissue Heart Valve Market
4.4 DRIVERS AND LIMITERS
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 COMPETITIVE MARKET SHARE ANALYSIS

ABBREVIATIONS

APPENDIX: COMPANY PRESS RELEASES

List of Charts
Chart 1 1: Cardiac Surgery and Heart Valve Devices Market by Segment, U.S., 2014 – 2024
Chart 1 2: Cardiac Surgery and Heart Valve Devices Market Overview, U.S., 2017 & 2024
Chart 4 1: Tissue Heart Valve Market by Device Type, U.S., 2014 – 2024
Chart 4 2: Tissue Heart Valve Market Breakdown by Device Type, U.S., 2017
Chart 4 3: Tissue Heart Valve Market Breakdown by Device Type, U.S., 2024
Chart 4 4: Tissue Heart Valve Market by Tissue Type, U.S., 2014 – 2024
Chart 4 5: Tissue Heart Valve Market Breakdown by Tissue Type, U.S., 2017
Chart 4 6: Tissue Heart Valve Market Breakdown by Tissue Type, U.S., 2024
Chart 4 7: Total Tissue Heart Valve Market, U.S., 2014 – 2024
Chart 4 8: Stented Tissue Heart Valve Market, U.S., 2014 – 2024
Chart 4 9: Stentless Tissue Heart Valve Market, U.S., 2014 – 2024
Chart 4 10: Xenograft Tissue Heart Valve Market, U.S., 2014 – 2024
Chart 4 11: Allograft Tissue Heart Valve Market, U.S., 2014 – 2024
Chart 4 12: Leading Competitors, Tissue Heart Valve Market, U.S., 2017

List of Figures:
Figure 1 1: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (1 of 4)
Figure 1 2: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (2 of 4)
Figure 1 3: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (3 of 4)
Figure 1 4: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (4 of 4)
Figure 1 5: Companies Researched in this Report, U.S., 2017
Figure 1 6: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (1 of 4)
Figure 1 7: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (2 of 4)
Figure 1 8: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (3 of 4)
Figure 1 9: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (4 of 4)
Figure 1 10: Recent Events in the Cardiac Surgery and Heart Valve Devices Market, U.S., 2015 – 2017
Figure 1 11: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (1 of 4)
Figure 1 12: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (2 of 4)
Figure 1 13: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (3 of 4)
Figure 1 14: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (4 of 4)
Figure 1 15: Procedure Codes Investigated, U.S., 2017
Figure 1 16: Cardiac Surgery and Heart Valve Devices Markets Covered, U.S., 2017 (1 of 2)
Figure 1 17: Cardiac Surgery and Heart Valve Devices Markets Covered, U.S., 2017 (2 of 2)
Figure 1 18: Key Report Updates (1 of 2)
Figure 1 19: Key Report Updates (2 of 2)
Figure 1 20: Version History
Figure 3 1: Tissue Heart Valves by Company
Figure 3 2: Mechanical Tissue Heart Valves by Company
Figure 3 3: Annuloplasty Repair Devices by Company
Figure 3 4: Transcatheter Heart Valve Replacement Devices by Company
Figure 3 5: Transcatheter Mitral Valve Repair Devices by Company
Figure 3 6: On-Pump Coronary Artery Bypass Devices by Company
Figure 3 7: Off-Pump Coronary Artery Bypass Devices by Company
Figure 3 8: Endoscopic Vessel Harvesting Devices by Company
Figure 3 9: Anastomosis Assist Devices by Company
Figure 3 10: Transmyocardial Revascularization Devices by Company
Figure 3 11: Ventricular Assist Devices by Company
Figure 3 12: Intra-Aortic Balloon Devices by Company
Figure 3 13: Temporary Artificial Heart Replacement Devices by Company
Figure 3 14: Remote Hemodynamic Monitoring System Devices by Company
Figure 3 15: Patent Foramen Ovale Devices by Company
Figure 3 16: Atrial & Ventricular Septal Defect Devices by Company
Figure 3 17: Left Atrial Appendage Closure Devices by Company
Figure 3 18: Extracorporeal Membrane Oxygenation Machine by Company
Figure 3 19: Class 2 Device Recall MAQUET
Figure 3 20: Class 2 Device Recall MAQUET
Figure 3 21: Class 2 Device Recall MAQUET
Figure 3 22: Class 1 Device Recall Medtronic
Figure 3 23: Class 1 Device Recall Heartware Inc
Figure 3 24: The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study
Figure 3 25: Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance
Figure 3 26: Medtronic CoreValve Evolut R U.S. Clinical Study
Figure 3 27: Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients
Figure 3 28: AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption
Figure 3 29: AMPLATZER Duct Occluder II Additional Sizes (ADO II AS)
Figure 3 30: HeartMate 3 CE Mark Study Long Term Follow-up (HM3 CE LTFU)
Figure 3 31: Trifecta™ GT Post Market Clinical Follow-up
Figure 3 32: AMPLATZER™ LAA Occluder Post Approval Study (PAS)
Figure 3 33: AMPLATZER™ Cardiac Plug Observational Post-Approval Study (ACP PAS China)
Figure 3 34: MOMENTUM 3 Continued Access Protocol (MOMENTUM 3 CAP)
Figure 3 35: AMPLATZER™ Amulet™ LAA Occluder Trial (Amulet IDE)
Figure 3 36: Prevention of Non-Surgical Bleeding by Management of HeartMate II
Figure 3 37: Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction (DTU)
Figure 3 38: Protected PCI Study
Figure 3 39: Assessment of the WATCHMAN™ Device
Figure 3 40: Watchman FLX Left Atrial Appendage Closure Device Post Approval Study
Figure 3 41: Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
Figure 4 1: Tissue Heart Valve Market by Device Type, U.S., 2014 – 2024 (US$M)
Figure 4 2: Tissue Heart Valve Market by Tissue Type, U.S., 2014 – 2024 (US$M)
Figure 4 3: Total Tissue Heart Valve Market, U.S., 2014 – 2024
Figure 4 4: Stented Tissue Heart Valve Market, U.S., 2014 – 2024
Figure 4 5: Stentless Tissue Heart Valve Market, U.S., 2014 – 2024
Figure 4 6: Xenograft Tissue Heart Valve Market, U.S., 2014 – 2024
Figure 4 7: Allograft Tissue Heart Valve Market, U.S., 2014 – 2024
Figure 4 8: Drivers and Limiters, Tissue Heart Valve Market, U.S., 2017
Figure 4 9: Leading Competitors, Tissue Heart Valve Market, U.S., 2017
Figure 6 1: Press Release Summary
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Edwards Lifesciences
  • St. Jude Medical
  • Medtronic
  • Maquet
  • Abiomed
  • HeartWare Inc.
  • Sorin Group
  • Terumo
  • Abbott Laboratories
  • Teleflex Medical
  • Cardiac Assist
  • AtriCure
  • W.L. Gore
  • SynCardia
  • Boston Scientific
  • Cryolife
  • Berlin Heart
  • Cardica
  • Chase Medical
  • Genesee Biomedical
  • Karl Storz
  • LifeNet Health
  • Microline Surgical
  • Novadaq
  • On-X
  • Saphena Medical
  • SentreHeart
  • Vitalitec
Please Note: Not all companies are currently active in every segment or sub-report from this suite.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll